My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
Related links
- Similars in SciELO
Share
Nucleus
Print version ISSN 0864-084X
Abstract
ONDARSE ALVAREZ, Dianelys et al. hR3 modification with DOTA-NHS. 90Y labeling and biodistribution. Nucleus [online]. 2011, n.49, pp.26-32. ISSN 0864-084X.
ABSTRACT The conjugation, characterization and biodistribution of -DOTA-hR3 radioimmunoconjugate are reported in this work. DOTA was used as bifunctional chelating agent. Molar ratios 320:1, 160:1 and 88:1 DOTA/monoclonal antibody hR3 were studied in order to evaluate their influence on the integrity of conjugate and labeling efficiency. In vivo stability of -DOTA-hR3 radioimmunoconjugates was determined in healthy Wistar rats at 4, 24 and 48 h after the injection. Stability studies performed by means of DTPA challenge showed that the compound is stable in a wide period of time (up to 216 h). In vivo stability studies, based on the bone uptake, showed that the radiometal release from the radioimmunoconjugate is not significant in the first 48 hours.
Keywords : yttrium 90; labelling; monoclonal antibodies; in vivo.